PMID: 9185206May 1, 1997Paper

Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results

Pediatric Hematology and Oncology
A SchiavettiV Colloridi

Abstract

The objective of this study is to assess the efficacy of ICRF-187 as a protective agent against anthracycline cardiotoxicity. Cardiac function was evaluated by echocardiography before and after each cycle of anthracycline chemotherapy associated with ICRF-187 and compared with that of a second group receiving anthracycline chemotherapy without ICRF-187. The patients were a group of 15 consecutive children affected with various types of solid tumors who were treated with either doxorubicin-daunomycin or epirubicin (average doses 340 and 280 mg/m2, respectively), and treatment was associated with ICRF-187. A second group of 15 consecutive children affected with different malignancies were simultaneously treated with either doxorubicin-daunomycin or epirubicin (average doses 309 and 270 mg/m2, respectively), but without ICRF-187 association. None of the patients treated with anthracyclines and ICRF-187 association showed abnormalities on echocardiographic examination. In the second group of patients treated with anthracyclines but without ICRF-187 association, we observed a decrease in the left ventricular ejection fraction to < 55% and a decrease in the left ventricular fractional shortening to < 28% in two patients (13.3%). One ...Continue Reading

References

Apr 1, 1978·Cancer·K R BloomM A Gribbin
Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Sep 1, 1976·Cancer Treatment Reviews·L Lenaz, J A Page
Feb 1, 1976·Cancer·A C GilladogaM L Murphy
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D NielsenM Hansen
Jun 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Italian Multicentre Breast Study with EpirubicinC Intini
May 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H PegelowJ R Wilbur
Feb 1, 1982·Annals of Internal Medicine·S S LeghaE J Freireich
Oct 1, 1981·The Journal of Clinical Investigation·J H DoroshowC E Myers
Jan 1, 1993·Surgical Oncology·T W MeskoH Nava
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H WexlerM E Horowitz

❮ Previous
Next ❯

Citations

Jul 22, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lubomir ElblJaroslav Michalek
Oct 16, 1999·British Journal of Haematology·G Levitt
Jul 13, 2004·The New England Journal of Medicine·Steven E LipshultzStephen E Sallan
Nov 6, 2010·The Oncologist·Dana M SepeFrank M Balis
Jun 28, 2005·Paediatric Drugs·Valeriano C SimbreSteven E Lipshultz
Mar 29, 2014·Pediatric Blood & Cancer·Alix E SeifRichard Aplenc
Jun 30, 2004·Human & Experimental Toxicology·Mehmet Emin BüyükokuroğluEbubekir Bakan
Nov 28, 2007·Experimental Biology and Medicine·Snezana K BjelogrlicViktor Jovic
May 20, 2008·Pediatric Hematology and Oncology·A RuggieroR Riccardi
May 1, 1997·Pediatric Hematology and Oncology·J Blatt
Mar 28, 2019·Current Cancer Drug Targets·Seema RohillaVinay Chawla
Jul 30, 2002·Prostaglandins, Leukotrienes, and Essential Fatty Acids·S HreliaP L Biagi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.